Graph Therapeutics adds $5M for precision immunology

AI in biotech is most interesting when it is tied closely to real biology. Graph Therapeutics is using patient-cell analysis and machine learning to make immunology research more precise.

What happened

Graph Therapeutics secured a new $5M investment, bringing its total funding to more than $10M.

The company uses live patient-cell analysis, multi-omics data and machine learning to develop precision medicines for inflammatory and immune-mediated diseases.

Why it matters

This is a clean AI x biotech signal.

Graph Therapeutics is using a lab-in-the-loop model, where biological experiments and machine learning feed into each other. That can help identify disease mechanisms, drug targets and biomarkers with more patient-specific context.

The bigger picture

The next phase of AI drug discovery may be less about generic model hype and more about tighter links between data, experiments and clinical biology. Startups that can connect all three may have a stronger path to useful medicines.